46.99
+0.01(+0.02%)
Currency In USD
| Previous Close | 46.99 |
| Open | 46.99 |
| Day High | 46.99 |
| Day Low | 46.99 |
| 52-Week High | 62 |
| 52-Week Low | 28.21 |
| Volume | 5.01M |
| Average Volume | 5.85M |
| Market Cap | 3.54B |
| PE | -13.78 |
| EPS | -3.41 |
| Moving Average 50 Days | 45.88 |
| Moving Average 200 Days | 41.19 |
| Change | 0.01 |
If you invested $1000 in SpringWorks Therapeutics, Inc. (SWTX) since IPO date, it would be worth $2,076.45 as of September 08, 2025 at a share price of $46.99. Whereas If you bought $1000 worth of SpringWorks Therapeutics, Inc. (SWTX) shares 5 years ago, it would be worth $1,083.22 as of September 08, 2025 at a share price of $46.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
GlobeNewswire Inc.
Aug 18, 2025 1:10 PM GMT
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt,
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire Inc.
Jul 18, 2025 3:30 PM GMT
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringW
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
GlobeNewswire Inc.
Jun 20, 2025 12:00 PM GMT
– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, Conn., June 20, 2025 (